Exploratory subgroup analysis of FIRE-3 (352 patients, RAS wild-type metastatic colorectal cancer): cetuximab vs bevacizumab with FOLFIRI improved OS in men with left-sided tumours (HR 0.66), but worsened PFS in women with right-sided tumours (HR 4.95).
Secondary analysisn = 352 patients
Heinrich et al. Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial